Stay updated with breaking news from Gild alice. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Gilead Sciences (NASDAQ:GILD – Free Report) had its price target decreased by TD Cowen from $90.00 to $85.00 in a report released on Friday, Benzinga reports. TD Cowen currently has a buy rating on the biopharmaceutical company’s stock. Several other research analysts have also commented on GILD. Wells Fargo & Company decreased their price target […] ....
Bahl & Gaynor Inc. decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 7.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 13,390 shares of the biopharmaceutical company’s stock after selling 1,155 shares during the quarter. Bahl & Gaynor Inc.’s […] ....
Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) announced a quarterly dividend on Thursday, April 25th, Zacks reports. Stockholders of record on Friday, June 14th will be paid a dividend of 0.77 per share by the biopharmaceutical company on Thursday, June 27th. This represents a $3.08 dividend on an annualized basis and a dividend yield […] ....
Gilead Sciences (NASDAQ:GILD – Get Free Report) had its target price decreased by stock analysts at Morgan Stanley from $80.00 to $78.00 in a report released on Friday, Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s target price indicates a potential upside of 18.88% from the […] ....
Gilead Sciences (NASDAQ:GILD – Get Free Report) had its target price dropped by equities researchers at Morgan Stanley from $80.00 to $78.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective indicates a potential […] ....